Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

Providing radiologists with key details about the patient's symptoms can go a long way toward improving the quality of their work. 

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.

The hope is that by creating detectors that are more sensitive, less ionizing radiation will be needed to produce diagnostic quality imaging.

A recent analysis of an already CE-marked, AI-based system that identifies pneumothorax on chest radiographs revealed a weak point in what has largely been considered a reliable support tool. 

Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.

Using computed tomography allows researchers to study these individuals in a more sensitive, person-centered approach.